ACZ885U
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2020 | $530,884 | 25 | 1 |
| 2019 | $1.8M | 26 | 0 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $2.3M | 51 | 100.0% |
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A PHASE III RANDOMIZED STUDY OF CANAKINUMAB + PEMBROLIZUMAB ALONE AS MAINTENACE THERAPY FOLLOWING CHEMOTHERAPY + PEMBROLIZUMAB INDUCTION THERAPY IN PREVIOUSLY UNTREATED ADULT PATIENTS WITH STAGE IIIB OR IV NON-SMALL CELL LUNG CANCER. | Novartis Pharmaceuticals Corporation | $2.3M | 0 |
| RESEARCH RELATED PUBLICATIONS SUPPORT | Novartis Pharmaceuticals Corporation | $5,625 | 1 |
Top Doctors Receiving Payments for ACZ885U
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Chicago, IL | $2.3M | 50 |
| , M.D | Medical Oncology | Fairfax, VA | $5,625 | 1 |
Manufacturing Companies
Product Information
- Type Drug
- Total Payments $2.3M
- Total Doctors 1
- Transactions 51
About ACZ885U
ACZ885U is a drug associated with $2.3M in payments to 1 healthcare providers, recorded across 51 transactions in the CMS Open Payments database. The primary manufacturer is Novartis Pharmaceuticals Corporation.
Payment data is available from 2019 to 2020. In 2020, $530,884 was paid across 25 transactions to 1 doctors.
The most common payment nature for ACZ885U is "Unspecified" ($2.3M, 100.0% of total).
ACZ885U is associated with 2 research studies, including "A PHASE III RANDOMIZED STUDY OF CANAKINUMAB + PEMBROLIZUMAB ALONE AS MAINTENACE THERAPY FOLLOWING CHEMOTHERAPY + PEMBROLIZUMAB INDUCTION THERAPY IN PREVIOUSLY UNTREATED ADULT PATIENTS WITH STAGE IIIB OR IV NON-SMALL CELL LUNG CANCER." ($2.3M).